Research

Hormonal

Small-molecule GLP-1 receptor agonists (e.g., orforglipron) are pharmacologically inactive in standard wild-type mice due to species-specific receptor binding differences, requiring humanized GLP-1 receptor (hGLP1R) mouse models to accurately predict human metabolic efficacy.

If you are evaluating or using small-molecule GLP-1 drugs (like orforglipron), standard animal testing will not show their effects. These drugs require a humanized receptor to work in mice. This highlights why human clinical trials are essential for this specific class of drugs, as animal models cannot predict their efficacy.

GoodQualifiesHIGH confidence
Previous structural and pharmacological reports have demonstrated that orforglipron and danuglipron are inactive at the mouse GLP1R... The species-specific receptor activation by small-molecule GLP1RAs poses a significant challenge in advancing this compound class toward clinical development, as standard rodent models fail to translate study outcomes to human settings.
Nina Sonne et al. · EBioMedicine · 2026

Why this rating

High-quality in vivo pharmacological validation using multiple endpoints (cAMP, glucose tolerance, body weight) in a rigorously engineered animal model.

Source

Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development

Nina Sonne et al. · EBioMedicine · 2026

DOI 10.1016/j.ebiom.2026.106121

mechanism_onlyCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →